Regulatory & Policy Intelligence
Strategic monitoring of global regulatory evolution, accelerated approval frameworks and pharmaceutical compliance developments.
Regulatory reform directly influences drug approval timelines, market access dynamics and innovation incentives across major jurisdictions.
Covering Nearly 20 Rare Diseases: A Comprehensive Overview of Newly Approved Rare Disease Drugs Worldwide in March 2026
April 16, 2026
A comprehensive review of nearly 20 newly approved rare disease drugs worldwide in March 2026, covering hematology, oncology, metabolic disorders, and gene therapy.
2026 Global Innovative Drug R&D and Regulatory Dynamics: ADC and Gene Therapies Lead a New Era
April 10, 2026
In 2026, global innovative drug R&D continues to accelerate, with Antibody-Drug Conjugates (ADCs) and gene therapies taking center stage. This article deeply analyzes the latest approval dynamics from the FDA and NMPA, and explores how these cutting-edge technologies are reshaping the landscape of oncology and rare disease treatments.
Global Pharmaceutical Innovation and Regulatory Dynamics in 2026: Breakthroughs in Oncology and Rare Diseases
April 09, 2026
Why β₁-Selective Beta-Blockers Remain Important in Cardiovascular Therapy
March 30, 2026
Explore why β₁-selective beta-blockers like bisoprolol remain essential in cardiovascular therapy, with improved safety and targeted mechanisms.
Where to Access RNA Therapy: Global Availability and Cross-Border Supply Systems (2026)
March 28, 2026
NMPA vs FDA Drug Approval: Key Differences Between China and US Regulatory Systems
March 27, 2026
2026 List of Approved Oncology Drugs in China (NMPA Guide) and Practical Reference for Overseas Procurement
March 25, 2026
Guide to Cross-Border Pharmaceutical Distribution: Compliance from Transport to Customs Clearance
March 24, 2026
A practical guide to cross-border pharmaceutical distribution, covering cold chain logistics, customs declaration, clearance risks, and compliance strategies.
February 2026 Approvals Signal China’s Entry into Core MAPK, JAK, and IL-17 Pathway Competition
March 16, 2026
China Approves New Indication for Herombopag in Severe Aplastic Anemia
March 16, 2026
Chinese Pharmaceutical Companies Achieve FDA First Generic Drug Approvals in 2025
March 14, 2026
China Pharmaceutical Distribution Industry Trends: Compliance Upgrades, Digital Transformation, and Supply Chain Opportunities in 2026
March 12, 2026
New Advances in BRAF-Mutant Colorectal Cancer: Why the Encorafenib Combination Therapy Is Drawing Attention
March 12, 2026
Southeast Asia’s Drug Approval Gap: Why Access to Innovative Therapies Is Lagging
March 11, 2026
World’s First Semaglutide Nasal Spray Approved by the FDA to Enter Clinical Trials
March 10, 2026
The FDA has approved the world’s first semaglutide nasal spray to enter clinical trials, marking a potential breakthrough in GLP-1 drug delivery technology.
Birociclib Approved for First-Line Indication: China’s First CDK4/6 Inhibitor Covering the Full Spectrum from First- to Late-Line Treatment
March 06, 2026
China’s NMPA has approved a new first-line indication for Birociclib, making it the first CDK4/6 inhibitor in China to cover the full treatment spectrum for HR+/HER2− advanced breast cancer.